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Abstract Opiate substitution treatment and needle
exchanges have reduced blood borne virus (BBV) trans-
mission among people who inject drugs (PWID). Psy-
chosocial interventions could further prevent BBV. A
systematic review and meta-analysis examined whether
psychosocial interventions (e.g. CBT, skills training) com-
pared to control interventions reduced BBV risk behaviours
among PWID. 32 and 24 randomized control trials (2000-
May 2015 in MEDLINE, PsycINFO, CINAHL, Cochrane
Collaboration and Clinical trials, with an update in MED-
LINE to December 2016) were included in the review and
meta-analysis respectively. Psychosocial interventions
appear to reduce: sharing of needles/syringes compared to
education/information (SMD -0.52; 95% CI -1.02 to
-0.03; I2 = 10%; p = 0.04) or HIV testing/counselling
(SMD-0.24; 95% CI-0.44 to-0.03; I2 = 0%; p = 0.02);
sharing of other injecting paraphernalia (SMD -0.24; 95%
CI-0.42 to-0.06; I2 = 0%; p\ 0.01) and unprotected sex
(SMD-0.44; 95% CI-0.86 to-0.01; I2 = 79%; p = 0.04)
compared to interventions of a lesser time/intensity, how-
ever, moderate to high heterogeneity was reported. Such
interventions could be included with other harm reduction
approaches to prevent BBV transmission among PWID.
Resumen El tratamiento de sustitucio´n de opia´ceos y los
programas de intercambio de jeringuillas han disminuido
la transmisio´n de virus transmitidos por sangre (VTS) entre
los usuarios de drogas inyectadas (UDI). Las intervencio-
nes psicosociales podrı´an prevenir la transmisio´n de VTS.
Mediante una revisio´n sistema´tica con meta-ana´lisis, se
estudio´ si las intervenciones psicosociales (p.e. CBT,
entrenamiento en habilidades) redujeron los comporta-
mientos de riesgo asociados a los VTS entre UDI, en
comparacio´n con las intervenciones control. Se incluyeron
32 y 24 ensayos clı´nicos aleatorizados en la revisio´n y
meta-ana´lisis, respectivamente (2000-mayo 2015 en
MEDLINE, PsycINFO, CINAHL, Colaboracio´n Cochrane
y Clinical Trials, con una actualizacio´n en MEDLINE
hasta diciembre de 2016). Las intervenciones psicosociales
disminuyen los siguientes comportamientos de riesgo:
compartir agujas/jeringuillas en comparacio´n con la edu-
cacio´n/informacio´n (DME -0.52; IC del 95%: -1.02,
-0.03; I2 = 10%; p = 0.04) o en comparacio´n con ase-
soramiento/pruebas para el VIH (DME -0.24; IC del 95%:
-0.44, -0.03; I2 = 0%, p = 0.02); compartir otros
utensilios de inyeccio´n (DME -0.24; IC del 95%: -0.42,
Electronic supplementary material The online version of this
article (doi:10.1007/s10461-017-1755-0) contains supplementary
material, which is available to authorized users.
& Gail Gilchrist
gail.gilchrist@kcl.ac.uk
1 National Addiction Centre, Institute of Psychiatry,
Psychology and Neuroscience, King’s College London, 4
Windsor Walk, London SE5 8BB, UK
2 Department of General Practice, University of Melbourne,
Parkville, VIC 3010, Australia
3 Department of Psychiatry and Clinical Psychobiology,
School of PsychologyUniversity of Barcelona,
08036 Barcelona, Spain
4 University of Huddersfield, Huddersfield HD1 3DH, UK
5 Mental Health and Addiction Research Group, Department of
Health Sciences, University of York, York YO24 2YD, UK
6 School for Health and Related Research, University of
Sheffield, Regent Court, 30 Regent Street, Sheffield S1 4DA,
UK
7 Addiction Research Group, IMIM-Institut Hospital del Mar
d’Investigacions Me`diques, Institute of Neuropsychiatry and
Addictions, Parc de Salut Mar de Barcelona,
08003 Barcelona, Spain
123
AIDS Behav
DOI 10.1007/s10461-017-1755-0
T
a
b
le
1
D
es
cr
ip
ti
o
n
o
f
tr
ia
ls
in
cl
u
d
ed
in
th
e
sy
st
em
at
ic
re
v
ie
w
an
d
m
et
a-
an
al
y
se
s
A
u
th
o
rs
P
ar
ti
ci
p
an
ts
(%
fe
m
al
e)
In
te
rv
en
ti
o
n
d
el
iv
er
y
se
tt
in
g
/s
ta
ff
In
te
rv
en
ti
o
n
g
ro
u
p
d
es
cr
ip
ti
o
n
C
o
n
tr
o
l
g
ro
u
p
d
es
cr
ip
ti
o
n
L
en
g
th
o
f
fo
ll
o
w
-u
p
In
te
rv
en
ti
o
n
g
ro
u
p
/s
N
u
m
b
er
o
f
se
ss
io
n
s
In
te
rv
en
ti
o
n
fu
n
ct
io
n
/s
C
o
n
tr
o
l
in
te
rv
en
ti
o
n
N
u
m
b
er
o
f
se
ss
io
n
s
A
b
o
u
-S
al
eh
et
al
.
[3
1
]
9
5
H
C
V
-v
e
P
W
ID
(2
6
%
)
O
u
tp
at
ie
n
t
d
ru
g
tr
ea
tm
en
t/
tr
ea
tm
en
t
st
af
f
E
n
h
an
ce
d
p
re
v
en
ti
o
n
co
u
n
se
ll
in
g
(N
=
4
3
)
4
9
4
0
–
6
0
m
in
se
ss
io
n
s
E
d
u
ca
ti
o
n
,
en
ab
le
m
en
t
S
im
p
le
ed
u
ca
ti
o
n
al
co
u
n
se
ll
in
g
(N
=
5
2
)
1
9
1
0
m
in
se
ss
io
n
6
m
o
n
th
s
p
o
st
ra
n
d
o
m
is
at
io
n
A
v
an
ts
et
al
.
[3
2
]
2
2
0
P
W
ID
in
m
et
h
ad
o
n
e
m
ai
n
te
n
an
ce
tr
ea
tm
en
t
(M
M
T
)
(6
9
%
)
M
M
T
/c
li
n
ic
ia
n
S
ta
n
d
ar
d
ca
re
?
h
ar
m
re
d
u
ct
io
n
g
ro
u
p
(N
=
1
0
8
)
1
2
9
9
0
m
in
w
ee
k
ly
g
ro
u
p
se
ss
io
n
s
E
d
u
ca
ti
o
n
,
en
ab
le
m
en
t,
tr
ai
n
in
g
S
ta
n
d
ar
d
ca
re
?
si
n
g
le
H
IV
ri
sk
re
d
u
ct
io
n
se
ss
io
n
(N
=
1
1
2
)
1
9
2
h
se
ss
io
n
P
o
st
in
te
rv
en
ti
o
n
B
er
tr
an
d
et
al
.
[3
3
]
2
1
9
P
W
ID
th
at
sh
ar
ed
d
ru
g
s
o
r
in
je
ct
io
n
eq
u
ip
m
en
t
(1
8
%
)
N
o
t
sp
ec
ifi
ed
/r
es
ea
rc
h
er
M
o
ti
v
at
io
n
al
in
te
rv
en
ti
o
n
(M
I)
(N
=
1
1
1
)
1
se
ss
io
n
E
n
ab
le
m
en
t,
p
er
su
as
io
n
E
d
u
ca
ti
o
n
In
te
rv
en
ti
o
n
(N
=
1
0
8
)
1
9
3
0
–
4
5
m
in
6
m
o
n
th
s
p
o
st
ra
n
d
o
m
is
at
io
n
B
o
o
th
et
al
.
[1
7
]
6
3
2
P
W
ID
(2
4
%
)
R
es
id
en
ti
al
d
et
o
x
ifi
ca
ti
o
n
/
in
te
rv
en
ti
o
n
is
t
T
re
at
m
en
t
as
u
su
al
(T
A
U
)
?
H
IV
/H
C
V
co
u
n
se
ll
in
g
an
d
ed
u
ca
ti
o
n
(C
&
E
)
(N
=
2
1
2
)
T
A
U
?
in
te
rv
en
ti
o
n
to
fa
ci
li
ta
te
tr
ea
tm
en
t
en
tr
y
(N
=
2
0
9
)
2
in
d
iv
id
u
al
se
ss
io
n
s
in
d
iv
id
u
al
se
ss
io
n
E
d
u
ca
ti
o
n
,
en
ab
le
m
en
t,
tr
ai
n
in
g
T
A
U
:
H
IV
/H
C
V
ri
sk
as
se
ss
m
en
t
sc
re
en
in
g
an
d
re
fe
rr
al
fo
r
te
st
in
g
an
d
co
u
n
se
ll
in
g
(N
=
2
1
1
)
H
IV
/H
C
V
ri
sk
as
se
ss
m
en
t
sc
re
en
in
g
an
d
re
fe
rr
al
fo
r
te
st
in
g
an
d
co
u
n
se
ll
in
g
6
m
o
n
th
s
p
o
st
ra
n
d
o
m
is
at
io
n
D
u
sh
ay
et
al
.
[3
4
]
6
6
9
d
ru
g
u
se
rs
[6
4
%
in
je
ct
in
g
]
(2
7
%
)
N
o
t
re
p
o
rt
ed
E
th
n
ic
cu
lt
u
ra
l
en
h
an
ce
d
in
te
rv
en
ti
o
n
(n
=
4
5
3
)
5
se
ss
io
n
s
E
d
u
ca
ti
o
n
,
en
ab
le
m
en
t,
tr
ai
n
in
g
A
ID
S
v
id
eo
ed
u
ca
ti
o
n
al
p
ro
g
ra
m
m
e
(N
=
2
1
6
)
2
v
id
eo
se
ss
io
n
s
5
–
1
0
m
o
n
th
s
p
o
st
ra
n
d
o
m
is
at
io
n
(2
0
%
in
te
rv
ie
w
ed
1
2
m
o
n
th
s
p
o
st
ra
n
d
o
m
is
at
io
n
)
E
l-
B
as
se
ll
et
al
.
[3
5
]
2
8
2
H
IV
-
n
eg
at
iv
e
d
ru
g
-
u
si
n
g
co
u
p
le
s
(1
6
%
P
W
ID
)
(5
0
%
)
N
o
t
re
p
o
rt
ed
/t
ra
in
ed
fa
ci
li
ta
to
r
C
o
u
p
le
-b
as
ed
ri
sk
re
d
u
ct
io
n
(n
=
1
9
0
)
In
d
iv
id
u
al
-b
as
ed
H
IV
ri
sk
re
d
u
ct
io
n
d
el
iv
er
ed
to
m
al
e
o
r
fe
m
al
e
d
ru
g
u
si
n
g
p
ar
tn
er
(n
=
1
8
3
)
7
se
ss
io
n
s
E
n
ab
le
m
en
t,
tr
ai
n
in
g
C
o
u
p
le
-b
as
ed
w
el
ln
es
s
p
ro
m
o
ti
o
n
(n
=
1
9
0
)
7
se
ss
io
n
s
1
2
m
o
n
th
s
p
o
st
ra
n
d
o
m
is
at
io
n
G
ag
n
o
n
et
al
.
[3
7
]
2
6
0
P
W
ID
(3
1
%
)
N
ee
d
le
ex
ch
an
g
e/
co
m
p
u
te
ri
se
d
in
te
rv
en
ti
o
n
S
ta
n
d
ar
d
in
te
rv
en
ti
o
n
(n
ee
d
le
ex
ch
an
g
es
,
p
sy
ch
o
so
ci
al
su
p
p
o
rt
an
d
so
ci
al
an
d
h
ea
lt
h
se
rv
ic
e
re
fe
rr
al
s)
?
co
m
p
u
te
r-
ta
il
o
re
d
m
es
sa
g
es
(N
=
1
3
0
)
4
se
ss
io
n
s
E
d
u
ca
ti
o
n
,
en
ab
le
m
en
t,
m
o
d
el
li
n
g
,
p
er
su
as
io
n
st
an
d
ar
d
in
te
rv
en
ti
o
n
(N
=
1
3
0
)
4
w
ee
k
s
3
m
o
n
th
s
p
o
st
in
te
rv
en
ti
o
n
G
ar
fe
in
et
al
.
[3
8
],
P
u
rc
el
l
et
al
.
[4
7
],
M
ac
k
es
y
-A
m
it
i
et
al
.
[4
2
,
6
0
,
6
1
]
6
5
4
H
IV
-v
e
an
d
H
C
V
-v
e
P
W
ID
(3
4
%
)
N
o
t
re
p
o
rt
ed
/t
ra
in
ed
fa
ci
li
ta
to
rs
P
ee
r
ed
u
ca
ti
o
n
(N
=
4
3
1
)
6
se
ss
io
n
s
E
d
u
ca
ti
o
n
,
en
ab
le
m
en
t,
tr
ai
n
in
g
V
id
eo
d
is
cu
ss
io
n
(N
=
4
2
3
)
6
se
ss
io
n
s
6
m
o
n
th
s
p
o
st
in
te
rv
en
ti
o
n
AIDS Behav
123
T
a
b
le
1
co
n
ti
n
u
ed
A
u
th
o
rs
P
ar
ti
ci
p
an
ts
(%
fe
m
al
e)
In
te
rv
en
ti
o
n
d
el
iv
er
y
se
tt
in
g
/s
ta
ff
In
te
rv
en
ti
o
n
g
ro
u
p
d
es
cr
ip
ti
o
n
C
o
n
tr
o
l
g
ro
u
p
d
es
cr
ip
ti
o
n
L
en
g
th
o
f
fo
ll
o
w
-u
p
In
te
rv
en
ti
o
n
g
ro
u
p
/s
N
u
m
b
er
o
f
se
ss
io
n
s
In
te
rv
en
ti
o
n
fu
n
ct
io
n
/s
C
o
n
tr
o
l
in
te
rv
en
ti
o
n
N
u
m
b
er
o
f
se
ss
io
n
s
G
il
b
er
t
et
al
.
[2
2
]
4
0
H
IV
-v
e
co
u
p
le
s
w
h
o
in
je
ct
d
ru
g
s
(5
0
%
)
N
ee
d
le
ex
ch
an
g
e/
fa
ci
li
ta
to
rs
C
o
u
p
le
b
as
ed
H
IV
ri
sk
re
d
u
ct
io
n
(2
0
co
u
p
le
s)
3
si
n
g
le
-g
en
d
er
g
ro
u
p
se
ss
io
n
s
?
co
u
p
le
se
ss
io
n
E
d
u
ca
ti
o
n
,
m
o
d
el
li
n
g
,
tr
ai
n
in
g
W
el
ln
es
s
p
ro
m
o
ti
o
n
co
n
d
it
io
n
(2
0
co
u
p
le
s)
4
g
ro
u
p
se
ss
io
n
s
3
m
o
n
th
s
p
o
st
in
te
rv
en
ti
o
n
G
o
et
al
.
[5
9
]
4
1
9
in
d
ex
H
IV
-
v
e
P
W
ID
(0
%
)
N
o
t
re
p
o
rt
ed
P
ee
r
n
et
w
o
rk
-o
ri
en
te
d
(N
=
2
1
0
)
6
se
ss
io
n
s
?
3
b
o
o
st
er
se
ss
io
n
s
E
d
u
ca
ti
o
n
,
en
ab
le
m
en
t,
tr
ai
n
in
g
T
A
U
?
H
IV
p
am
p
h
le
t
(N
=
2
0
9
)
n
/a
1
2
m
o
n
th
s
p
o
st
in
te
rv
en
ti
o
n
G
o
et
al
.
[3
0
]
4
5
5
H
IV
?
v
e
P
W
ID
(0
%
)
C
o
m
m
u
n
it
y
in
te
rv
en
ti
o
n
ed
u
ca
ti
o
n
se
ss
io
n
s
d
el
iv
er
ed
b
y
a
tr
ai
n
ed
co
m
m
u
n
it
y
m
o
b
il
iz
er
;
In
d
iv
id
u
al
H
IV
k
n
o
w
le
d
g
e
an
d
sk
il
l-
b
u
il
d
in
g
g
ro
u
p
se
ss
io
n
s
co
n
d
u
ct
ed
b
y
tw
o
fa
ci
li
ta
to
rs
In
d
iv
id
u
a
l
le
ve
l
H
IV
te
st
in
g
an
d
co
u
n
se
ll
in
g
,
p
lu
s
2
in
d
iv
id
u
al
p
o
st
-t
es
t
co
u
n
se
ll
in
g
se
ss
io
n
s,
2
sm
al
l
g
ro
u
p
se
ss
io
n
s
(H
IV
k
n
o
w
le
d
g
e
an
d
sk
il
l-
b
u
il
d
in
g
)
?
o
p
ti
o
n
al
d
y
ad
se
ss
io
n
(N
=
9
5
)
C
o
m
m
u
n
it
y
a
n
d
in
d
iv
id
u
a
l
le
ve
l
C
o
m
m
u
n
it
y
-w
id
e
p
ro
g
ra
m
m
e
co
n
si
st
in
g
o
f
a
2
-p
ar
t
v
id
eo
an
d
a
se
ri
es
o
f
6
H
IV
ed
u
ca
ti
o
n
se
ss
io
n
s
(N
=
1
3
2
)
4
in
d
iv
id
u
al
se
ss
io
n
s
?
2
g
ro
u
p
se
ss
io
n
s
?
o
p
ti
o
n
al
d
y
ad
se
ss
io
n
2
-p
ar
t
v
id
eo
an
d
a
se
ri
es
o
f
6
H
IV
ed
u
ca
ti
o
n
se
ss
io
n
s
E
d
u
ca
ti
o
n
,
en
ab
le
m
en
t,
tr
ai
n
in
g
ed
u
ca
ti
o
n
In
d
iv
id
u
a
l
le
ve
l
H
IV
te
st
in
g
an
d
co
u
n
se
ll
in
g
(N
=
8
9
)
C
o
m
m
u
n
it
y
le
ve
l
S
ta
n
d
ar
d
m
es
sa
g
es
o
n
H
IV
th
ro
u
g
h
v
il
la
g
e
w
ee
k
ly
p
u
b
li
c
lo
u
d
sp
ea
k
er
s
an
d
ed
u
ca
ti
o
n
al
p
am
p
h
le
ts
al
re
ad
y
b
ei
n
g
p
ro
v
id
ed
b
y
co
m
m
u
n
it
y
h
ea
lt
h
st
at
io
n
s
(N
=
1
3
9
)
2
se
ss
io
n
s
2
4
m
o
n
th
s
p
o
st
ra
n
d
o
m
is
at
io
n
H
o
ff
m
an
[2
3
]
4
3
2
P
W
ID
(3
3
%
)
R
es
ea
rc
h
ce
n
tr
e/
fa
ci
li
ta
to
rs
P
sy
ch
o
lo
g
ic
al
-c
o
m
m
u
n
ic
at
iv
e
b
eh
av
io
ra
l
tr
ai
n
in
g
P
ee
r
ed
u
ca
to
r
(N
=
9
9
)
N
et
w
o
rk
m
em
b
er
s
(N
=
1
2
7
)
7
g
ro
u
p
?
1
in
d
iv
id
u
al
se
ss
io
n
?
4
b
o
o
st
er
m
ee
ti
n
g
s
E
d
u
ca
ti
o
n
,
m
o
d
el
li
n
g
,
p
er
su
as
io
n
,
tr
ai
n
in
g
G
ro
u
p
se
ss
io
n
s
d
ev
o
te
d
to
ar
ea
s
o
f
in
te
re
st
(N
=
9
2
)
N
et
w
o
rk
m
em
b
er
s
(N
=
1
1
4
)
8
se
ss
io
n
s
2
4
m
o
n
th
s
p
o
st
ra
n
d
o
m
is
at
io
n
L
at
k
a
et
al
.
[4
1
],
K
ap
ad
ia
et
al
.
[5
8
]
4
1
8
H
C
V
?
v
e
P
W
ID
(2
4
%
)
3
re
se
ar
ch
si
te
s/
fa
ci
li
ta
to
rs
P
ee
r-
m
en
to
ri
n
g
b
eh
av
io
u
ra
l
in
te
rv
en
ti
o
n
(N
=
2
2
2
)
6
se
ss
io
n
s
E
d
u
ca
ti
o
n
,
tr
ai
n
in
g
V
id
eo
-d
is
cu
ss
io
n
(N
=
1
9
6
)
6
se
ss
io
n
s
6
m
o
n
th
s
p
o
st
in
te
rv
en
ti
o
n
L
at
k
in
et
al
.
[2
1
]
2
5
0
[4
7
%
P
W
ID
]
(3
9
%
)
C
li
n
ic
/i
n
d
ig
en
o
u
s
p
ar
a-
p
ro
fe
ss
io
n
al
fa
ci
li
ta
to
rs
S
m
al
l-
g
ro
u
p
w
h
ic
h
en
co
u
ra
g
ed
p
ee
r
o
u
tr
ea
ch
(N
=
8
1
)
1
0
g
ro
u
p
se
ss
io
n
s
E
n
ab
le
m
en
t,
ed
u
ca
ti
o
n
,
tr
ai
n
in
g
E
q
u
al
-a
tt
en
ti
o
n
co
n
tr
o
l
co
n
d
it
io
n
(N
=
3
6
)
1
0
se
ss
io
n
s
6
m
o
n
th
s
p
o
st
in
te
rv
en
ti
o
n
L
at
k
in
et
al
.
[1
8
,
5
7
]
4
1
4
n
et
w
o
rk
s
w
it
h
1
1
2
3
H
IV
-v
e
p
ar
ti
ci
p
an
ts
[9
1
%
P
W
ID
(3
%
in
T
h
ai
la
n
d
;
2
0
%
in
U
S
)
N
o
t
re
p
o
rt
ed
/f
ac
il
it
at
o
r
H
IV
co
u
n
se
ll
in
g
an
d
te
st
in
g
(C
&
T
)
?
g
ro
u
p
p
ee
r-
ed
u
ca
ti
o
n
(N
=
2
0
4
n
et
w
o
rk
s)
2
in
d
iv
id
u
al
?
6
g
ro
u
p
?
2
b
o
o
st
er
se
ss
io
n
s
E
d
u
ca
ti
o
n
,
en
ab
le
m
en
t,
p
er
su
as
io
n
,
tr
ai
n
in
g
H
IV
C
&
T
(N
=
2
1
0
n
et
w
o
rk
s)
2
se
ss
io
n
s
U
p
to
3
0
m
o
n
th
s
(2
4
in
T
h
ai
la
n
d
)
p
o
st
ra
n
d
o
m
is
at
io
n
M
ar
g
o
li
n
et
al
.
[4
3
]
9
0
P
W
ID
H
IV
?
v
e
en
te
ri
n
g
M
M
T
(3
0
%
)
M
M
T
/c
o
u
n
se
ll
o
r
E
n
h
an
ce
d
-M
M
T
(E
-M
M
P
)
(6
m
o
n
th
s
o
f
d
ai
ly
m
et
h
ad
o
n
e
an
d
w
ee
k
ly
in
d
iv
id
u
al
su
b
st
an
ce
ab
u
se
co
u
n
se
li
n
g
an
d
ca
se
m
an
ag
em
en
t)
?
H
IV
H
ar
m
R
ed
u
ct
io
n
P
ro
g
ra
m
(N
=
4
5
)
6
-s
es
si
o
n
s
E
n
ab
le
m
en
t,
p
er
su
as
io
n
,
tr
ai
n
in
g
E
n
h
an
ce
d
-M
M
T
(E
-
M
M
P
)
?
ac
ti
v
e
co
n
tr
o
l
th
at
in
cl
u
d
ed
h
ar
m
re
d
u
ct
io
n
co
m
p
o
n
en
ts
(N
=
4
5
)
6
se
ss
io
n
s
9
m
o
n
th
s
p
o
st
ra
n
d
o
m
is
at
io
n
AIDS Behav
123
T
a
b
le
1
co
n
ti
n
u
ed
A
u
th
o
rs
P
ar
ti
ci
p
an
ts
(%
fe
m
al
e)
In
te
rv
en
ti
o
n
d
el
iv
er
y
se
tt
in
g
/s
ta
ff
In
te
rv
en
ti
o
n
g
ro
u
p
d
es
cr
ip
ti
o
n
C
o
n
tr
o
l
g
ro
u
p
d
es
cr
ip
ti
o
n
L
en
g
th
o
f
fo
ll
o
w
-u
p
In
te
rv
en
ti
o
n
g
ro
u
p
/s
N
u
m
b
er
o
f
se
ss
io
n
s
In
te
rv
en
ti
o
n
fu
n
ct
io
n
/s
C
o
n
tr
o
l
in
te
rv
en
ti
o
n
N
u
m
b
er
o
f
se
ss
io
n
s
M
cM
ah
o
n
et
al
.
[4
4
,
4
5
]
3
3
0
H
IV
-v
e
d
ru
g
u
se
rs
[4
8
%
P
W
ID
]
(1
0
0
%
)
an
d
m
al
e
p
ar
tn
er
s
F
ie
ld
o
ffi
ce
/i
n
te
rv
en
ti
o
n
is
t
(1
)
C
o
u
p
le
-B
as
ed
H
IV
C
&
T
(N
=
1
1
0
)
[4
3
%
P
W
ID
]
(2
)
W
o
m
en
o
n
ly
re
la
ti
o
n
sh
ip
-f
o
cu
se
d
H
IV
C
&
T
(N
=
1
0
4
)
[5
1
%
P
W
ID
]
2
se
ss
io
n
s
2
se
ss
io
n
s
E
d
u
ca
ti
o
n
,
en
ab
le
m
en
t
H
IV
C
&
T
(N
=
1
1
6
)
[5
1
%
P
W
ID
]
2
se
ss
io
n
s
9
m
o
n
th
s
p
o
st
in
te
rv
en
ti
o
n
O
ti
as
h
v
il
i
et
al
.
[4
6
]
4
0
d
ru
g
u
se
rs
[9
8
%
P
W
ID
]
(0
%
)
an
d
d
ru
g
-f
re
e
fe
m
al
e
p
ar
tn
er
s
R
es
ea
rc
h
u
n
it
/c
o
u
n
se
ll
o
r
M
I
fo
r
d
ru
g
u
se
r
an
d
co
u
p
le
,
co
n
ti
n
g
en
cy
m
an
ag
em
en
t
?
n
al
tr
ex
o
n
e
(n
=
2
0
).
F
em
al
e
p
ar
tn
er
s
in
v
it
ed
to
at
te
n
d
co
u
p
le
s
co
u
n
se
ll
in
g
2
2
se
ss
io
n
s
E
n
ab
le
m
en
t,
in
ce
n
ti
v
is
at
io
n
E
d
u
ca
ti
o
n
se
ss
io
n
s.
R
ef
er
ra
ls
d
ru
g
tr
ea
tm
en
t
(n
=
2
0
)
2
2
se
ss
io
n
s
6
m
o
n
th
s
p
o
st
in
te
rv
en
ti
o
n
P
u
rc
el
l
et
al
.
[4
7
,
5
6
]
9
6
6
H
IV
?
v
e
P
W
ID
(3
6
%
)
N
o
t
re
p
o
rt
ed
/p
ee
rs
P
ee
r
m
en
to
ri
n
g
in
te
rv
en
ti
o
n
(N
=
4
8
6
)
1
0
se
ss
io
n
s
(7
g
ro
u
p
;
2
in
d
iv
id
u
al
;
1
‘p
ee
r
ac
ti
v
it
y
’)
E
d
u
ca
ti
o
n
,
en
ab
le
m
en
t,
tr
ai
n
in
g
V
id
eo
d
is
cu
ss
io
n
(N
=
4
8
0
)
8
se
ss
io
n
s
1
2
m
o
n
th
s
p
o
st
in
te
rv
en
ti
o
n
R
o
b
le
s
et
al
.
[4
8
]
5
5
7
P
W
ID
(4
%
)
A
ss
es
sm
en
t
fa
ci
li
ty
o
r
d
ru
g
tr
ea
tm
en
t/
n
u
rs
e
H
IV
/A
ID
S
ri
sk
in
te
rv
en
ti
o
n
?
co
u
n
se
ll
in
g
?
ca
se
m
an
ag
em
en
t
(N
=
2
8
5
)
2
se
ss
io
n
s
6
se
ss
io
n
s
E
d
u
ca
ti
o
n
,
E
n
ab
le
m
en
t,
tr
ai
n
in
g
H
IV
/A
ID
S
ri
sk
in
te
rv
en
ti
o
n
(N
=
2
7
2
)
2
se
ss
io
n
s
6
m
o
n
th
s
p
o
st
ra
n
d
o
m
is
at
io
n
R
o
th
er
am
-
B
o
ru
s
et
al
.
[4
9
]
an
d
H
er
sh
b
er
g
er
et
al
.
[4
0
]
1
1
1
6
d
ru
g
u
se
rs
[6
5
%
P
W
ID
]
(3
3
%
)
F
ie
ld
o
ffi
ce
/c
o
u
n
se
ll
o
rs
/
o
u
tr
ea
ch
w
o
rk
er
s
H
IV
C
&
T
?
H
IV
p
re
v
en
ti
o
n
p
ro
g
ra
m
m
e
(g
ro
u
p
sk
il
ls
fo
cu
se
d
w
o
rk
sh
o
p
s,
in
d
iv
id
u
al
co
u
n
se
ll
in
g
,
o
u
tr
ea
ch
/s
o
ci
al
ev
en
ts
)
(N
=
5
5
8
;
3
5
9
P
W
ID
)
2
H
IV
C
&
T
se
ss
io
n
s
?
5
se
ss
io
n
s
(2
g
ro
u
p
,
1
in
d
iv
id
u
al
?
C
2
st
ru
ct
u
re
d
o
u
tr
ea
ch
)
E
n
ab
le
m
en
t,
tr
ai
n
in
g
H
IV
C
&
T
(N
=
5
5
9
;
3
6
4
P
W
ID
)
2
se
ss
io
n
s
9
m
o
n
th
s
p
o
st
ra
n
d
o
m
is
at
io
n
S
am
et
et
al
.
[5
0
]
7
0
0
H
IV
?
v
e
w
it
h
ri
sk
y
se
x
an
d
h
ea
v
y
al
co
h
o
l
co
n
su
m
p
ti
o
n
[6
0
%
P
W
ID
]
(4
1
%
)
H
o
sp
it
al
se
tt
in
g
/p
ee
rs
H
ea
lt
h
y
re
la
ti
o
n
sh
ip
s
in
te
rv
en
ti
o
n
(n
=
3
5
0
;
2
1
2
P
W
ID
)
2
in
d
iv
id
u
al
?
3
sm
al
l
g
ro
u
p
se
ss
io
n
s
E
d
u
ca
ti
o
n
,
en
ab
le
m
en
t,
m
o
d
el
li
n
g
,
tr
ai
n
in
g
A
tt
en
ti
o
n
co
n
tr
o
l
(n
=
3
5
0
;
2
1
1
P
W
ID
)
2
in
d
iv
id
u
al
?
3
g
ro
u
p
se
ss
io
n
s
1
2
m
o
n
th
s
p
o
st
ra
n
d
o
m
is
at
io
n
S
ch
ro
ed
er
et
al
.
[2
0
]
an
d
E
p
st
ei
n
et
al
.
[3
6
]
8
1
d
ru
g
u
se
rs
[9
6
%
P
W
ID
]
(5
2
%
)
R
es
ea
rc
h
cl
in
ic
/c
o
u
n
se
ll
o
r
M
M
T
?
in
d
iv
id
u
al
co
u
n
se
ll
in
g
fo
ll
o
w
ed
b
y
1
2
w
ee
k
s
o
f
in
te
rv
en
ti
o
n
co
n
d
it
io
n
,
fo
ll
o
w
ed
b
y
a
1
2
-w
ee
k
st
an
d
ar
d
tr
ea
tm
en
t
(1
)
w
ee
k
ly
C
B
T
?
co
n
ti
n
g
en
t
v
o
u
ch
er
s
(C
M
)
(N
=
1
6
)
(2
)
w
ee
k
ly
C
B
T
?
n
o
n
co
n
ti
n
g
en
t
v
o
u
ch
er
s
(N
=
1
9
)
(3
)
C
M
p
lu
s
w
ee
k
ly
g
ro
u
p
th
er
ap
y
(N
=
2
2
)
2
9
w
ee
k
s
(m
et
h
ad
o
n
e
?
5
w
ee
k
ly
in
d
iv
id
u
al
co
u
n
se
ll
in
g
,
1
2
w
ee
k
s
o
f
in
te
rv
en
ti
o
n
,
fo
ll
o
w
ed
b
y
1
2
w
ee
k
s
st
an
d
ar
d
tr
ea
tm
en
t
E
d
u
ca
ti
o
n
,
E
n
ab
le
m
en
t,
In
ce
n
ti
v
is
at
io
n
M
o
d
el
li
n
g
,
tr
ai
n
in
g
S
ta
n
d
ar
d
d
o
se
o
f
m
et
h
ad
o
n
e
(7
0
–
8
0
m
g
/d
ay
)
?
?
w
ee
k
ly
in
d
iv
id
u
al
co
u
n
se
ll
in
g
(5
w
ee
k
s)
fo
ll
o
w
ed
b
y
1
2
w
ee
k
s
o
f
co
n
tr
o
l
co
n
d
it
io
n
,
fo
ll
o
w
ed
b
y
a
1
2
-w
ee
k
st
an
d
ar
d
tr
ea
tm
en
t
G
ro
u
p
th
er
ap
y
?
n
o
n
-
co
n
ti
n
g
en
t
v
o
u
ch
er
s
(N
=
2
4
)
2
9
w
ee
k
s
(m
et
h
ad
o
n
e
?
5
w
ee
k
ly
in
d
iv
id
u
al
co
u
n
se
ll
in
g
,
1
2
w
ee
k
s
o
f
in
te
rv
en
ti
o
n
,
fo
ll
o
w
ed
b
y
1
2
w
ee
k
s
st
an
d
ar
d
tr
ea
tm
en
t
P
o
st
in
te
rv
en
ti
o
n
S
te
in
et
al
.
[5
1
]
1
0
9
P
W
ID
w
h
o
d
ri
n
k
h
az
ar
d
o
u
sl
y
(3
8
%
)
R
es
ea
rc
h
si
te
/s
o
ci
al
w
o
rk
er
R
ef
er
ra
ls
fo
r
su
b
st
an
ce
u
se
an
d
m
ed
ic
al
tr
ea
tm
en
t
?
b
ri
ef
M
I
(N
=
6
0
)
2
se
ss
io
n
s
E
n
ab
le
m
en
t
R
ef
er
ra
ls
fo
r
su
b
st
an
ce
ab
u
se
an
d
m
ed
ic
al
tr
ea
tm
en
t
p
ro
v
id
ed
(N
=
4
9
)
n
/a
6
m
o
n
th
s
p
o
st
ra
n
d
o
m
is
at
io
n
AIDS Behav
123
T
a
b
le
1
co
n
ti
n
u
ed
A
u
th
o
rs
P
ar
ti
ci
p
an
ts
(%
fe
m
al
e)
In
te
rv
en
ti
o
n
d
el
iv
er
y
se
tt
in
g
/s
ta
ff
In
te
rv
en
ti
o
n
g
ro
u
p
d
es
cr
ip
ti
o
n
C
o
n
tr
o
l
g
ro
u
p
d
es
cr
ip
ti
o
n
L
en
g
th
o
f
fo
ll
o
w
-u
p
In
te
rv
en
ti
o
n
g
ro
u
p
/s
N
u
m
b
er
o
f
se
ss
io
n
s
In
te
rv
en
ti
o
n
fu
n
ct
io
n
/s
C
o
n
tr
o
l
in
te
rv
en
ti
o
n
N
u
m
b
er
o
f
se
ss
io
n
s
S
te
in
et
al
.
[5
2
]
1
0
9
P
W
ID
(3
6
%
)
O
u
tp
at
ie
n
t
ac
ad
em
ic
re
se
ar
ch
o
ffi
ce
/C
li
n
ic
al
P
sy
ch
o
lo
g
is
t
C
B
T
?
p
h
ar
m
ac
o
th
er
ap
y
fo
r
d
ep
re
ss
io
n
(N
=
5
3
)
8
C
B
T
se
ss
io
n
s
?
3
p
h
ar
m
ac
o
th
er
ap
y
v
is
it
s
E
d
u
ca
ti
o
n
,
E
n
ab
le
m
en
t,
T
ra
in
in
g
A
ss
es
sm
en
t
(N
=
5
6
)
A
ss
es
sm
en
t
v
is
it
9
m
o
n
th
s
p
o
st
ra
n
d
o
m
is
at
io
n
S
te
in
et
al
.
[5
3
]
2
7
7
H
C
V
-v
e
d
ru
g
u
se
rs
[2
8
%
P
W
ID
]
(3
7
%
)
N
o
t
st
at
ed
/i
n
te
rv
en
ti
o
n
is
t
M
I
(N
=
1
4
0
)
4
se
ss
io
n
s
E
d
u
ca
ti
o
n
,
en
ab
le
m
en
t,
p
er
su
as
io
n
L
ea
fl
et
ab
o
u
t
lo
ca
l
re
so
u
rc
es
(N
=
1
3
7
)
n
/a
2
4
m
o
n
th
s
p
o
st
ra
n
d
o
m
is
at
io
n
S
te
rk
et
al
.
[2
9
]
6
8
H
IV
-v
e
P
W
ID
(1
0
0
%
)
H
ea
lt
h
in
te
rv
en
ti
o
n
p
ro
je
ct
h
o
u
se
/i
n
te
rv
en
ti
o
n
is
ts
E
n
h
an
ce
d
M
I
(E
M
I)
(N
=
2
0
)
E
n
h
an
ce
d
n
eg
o
ti
at
io
n
in
te
rv
en
ti
o
n
(E
N
I)
(N
=
2
1
)
4
se
ss
io
n
s
4
se
ss
io
n
s
E
d
u
ca
ti
o
n
,
en
ab
le
m
en
t,
tr
ai
n
in
g
N
ID
A
st
an
d
ar
d
in
te
rv
en
ti
o
n
(N
=
2
7
)
2
se
ss
io
n
s
6
-m
o
n
th
s
(n
o
t
cl
ea
r
if
p
o
st
in
te
rv
en
ti
o
n
o
r
p
o
st
ra
n
d
o
m
is
at
io
n
)
S
tr
at
h
d
ee
et
al
.
[2
6
]
an
d
V
er
a
et
al
.
[5
5
]
5
8
4
S
ex
w
o
rk
er
s
w
h
o
in
je
ct
d
ru
g
s
(1
0
0
%
)
N
o
t
re
p
o
rt
ed
/c
o
u
n
se
ll
o
rs
In
te
ra
ct
iv
e
in
je
ct
io
n
ri
sk
an
d
d
id
ac
ti
c
se
x
u
al
ri
sk
in
te
rv
en
ti
o
n
(N
=
1
4
6
)
In
te
ra
ct
iv
e
se
x
u
al
ri
sk
an
d
d
id
ac
ti
c
in
je
ct
io
n
ri
sk
in
te
rv
en
ti
o
n
(N
=
1
4
8
)
In
te
ra
ct
iv
e
In
je
ct
io
n
an
d
S
ex
u
al
R
is
k
In
te
rv
en
ti
o
n
)
(N
=
1
4
6
)
1
se
ss
io
n
1
se
ss
io
n
1
se
ss
io
n
E
d
u
ca
ti
o
n
,
en
ab
le
m
en
t,
m
o
d
el
li
n
g
,
p
er
su
as
io
n
,
tr
ai
n
in
g
D
id
ac
ti
c
in
je
ct
io
n
an
d
se
x
u
al
ri
sk
in
te
rv
en
ti
o
n
(N
=
1
4
4
)
1
9
6
0
m
in
se
ss
io
n
1
2
m
o
n
th
s
p
o
st
ra
n
d
o
m
is
at
io
n
T
o
b
in
et
al
.
[2
5
]
2
2
7
P
W
ID
(4
5
%
)
R
es
ea
rc
h
cl
in
ic
/n
o
t
re
p
o
rt
ed
P
ee
r
ed
u
ca
to
r
in
te
rv
en
ti
o
n
(N
=
1
1
4
)
7
se
ss
io
n
s
(5
g
ro
u
p
?
1
in
d
iv
id
u
al
?
1
w
it
h
p
ar
ti
ci
p
an
t
an
d
en
ro
ll
ed
R
is
k
N
et
w
o
rk
M
em
b
er
s)
E
d
u
ca
ti
o
n
,
en
ab
le
m
en
t,
tr
ai
n
in
g
G
ro
u
p
in
fo
rm
at
io
n
(N
=
1
1
3
)
5
se
ss
io
n
s
1
8
m
o
n
th
s
p
o
st
in
te
rv
en
ti
o
n
T
u
ck
er
et
al
.
[5
4
]
1
4
5
P
W
ID
(2
6
%
)
O
u
t-
p
at
ie
n
t
cl
in
ic
al
an
d
re
se
ar
ch
o
rg
an
iz
at
io
n
/c
li
n
ic
al
re
se
ar
ch
er
T
ai
lo
re
d
b
ri
ef
b
eh
av
io
u
ra
l
in
te
rv
en
ti
o
n
(N
=
7
3
)
1
se
ss
io
n
E
d
u
ca
ti
o
n
,
en
ab
le
m
en
t
H
C
V
ed
u
ca
ti
o
n
al
le
afl
et
(N
=
7
2
)
n
/a
1
m
o
n
th
p
o
st
ra
n
d
o
m
is
at
io
n
W
ec
h
sb
er
g
et
al
.
[2
4
]
1
0
0
P
W
ID
(1
0
0
%
)
In
p
at
ie
n
t
d
et
o
x
ifi
ca
ti
o
n
/
p
sy
ch
o
lo
g
is
t
W
o
m
an
-f
o
cu
se
d
In
te
rv
en
ti
o
n
(N
=
5
1
)
2
se
ss
io
n
s
E
d
u
ca
ti
o
n
,
en
ab
le
m
en
t,
tr
ai
n
in
g
N
u
tr
it
io
n
in
te
rv
en
ti
o
n
(N
=
4
9
)
2
se
ss
io
n
s
3
m
o
n
th
s
p
o
st
ra
n
d
o
m
is
at
io
n
Z
u
le
et
al
.
[1
9
]
8
5
1
P
W
ID
(2
7
%
)
N
o
t
re
p
o
rt
ed
/l
ay
co
m
m
u
n
it
y
m
em
b
er
s
H
C
V
ri
sk
re
d
u
ct
io
n
M
I
(n
=
4
2
3
)
6
se
ss
io
n
s
E
d
u
ca
ti
o
n
,
en
ab
le
m
en
t,
m
o
d
el
li
n
g
,
p
er
su
as
io
n
V
id
eo
H
C
V
ed
u
ca
ti
o
n
al
in
te
rv
en
ti
o
n
(n
=
4
2
8
)
6
se
ss
io
n
s
1
2
m
o
n
th
s
p
o
st
ra
n
d
o
m
is
at
io
n
AIDS Behav
123
-0.06; I2 = 0%; p\ 0.01) y el sexo sin proteccio´n (DME
-0.44; IC del 95%: -0.86, -0.01; I2 = 79%; p = 0.04) en
comparacio´n con las intervenciones de menor duracio´n/
intensidad. Sin embargo, se ha detectado una heteroge-
neidad de moderada a alta. Tales intervenciones podrı´an
incluirse junto con otros enfoques de reduccio´n de dan˜os
para prevenir la transmisio´n de VTS entre los UDI.
Keywords People who inject drugs  Psychosocial
intervention  Blood borne virus  Injecting risk behaviour 
Sexual risk behaviour  Systematic review  Meta-analysis
Introduction
Among people who inject drugs (PWID), prevalence of the
Hepatitis C virus (HCV) and HIV is around 5–90% [1] and
\1–50% [2] respectively. While pre-exposure prophylaxis
for HIV [3] and treatment for HCV are effective [4], no
vaccine prevents HCV. Opiate substitution therapy (OST)
and needle exchanges effectively reduce HIV and HCV
among PWID [5]. Psychosocial interventions (e.g. moti-
vational interviewing, cognitive behavioural therapy and
contingency management) could further decrease blood
borne viruses (BBV) by educating PWID about transmis-
sion risks and developing strategies to avoid them.
Several systematic reviews and meta-analyses of psy-
chosocial interventions to reduce BBV risk behaviours
among drug users have reported modest effects [6–9].
Reviews conclude that harm reduction interventions,
especially OST and needle exchange programmes, have
reduced injecting risk behaviours, but have not prevented
HCV transmission among PWID [5]. In addition, combined
substance-use treatment and support for safe injection were
most effective in reducing HCV seroconversion among
PWID [6]. Interventions that target capability (i.e. indi-
vidual’s psychological and physical capacity to engage in
the activity concerned including having the necessary
knowledge and skills), opportunity (i.e. factors outside the
individual that make the behaviour possible or prompt it),
and motivation are thought to be more effective in
addressing behaviour change than interventions that
address one or fewer of these components [10]. In partial
support of this, two reviews concluded that multi-session
psychosocial interventions compared to educational inter-
ventions had minimal benefits on injecting risk behaviours
[7] and modest benefits on sexual risk behaviours among
people who use drugs [8]. In addition, large positive effects
were reported compared to minimal interventions for
reducing HIV sexual risk behaviours [8]. Despite these
promising findings, another review concluded that beha-
vioural interventions (peer-intervention training and coun-
selling interventions) were ‘‘unlikely … [to] have a
considerable effect on HCV transmission’’ for PWID (p.
176) [9].
PWID are more likely to have BBV than people who use
drugs but do not inject [11]. Alongside elevated risks from
sharing injecting equipment, some PWID report greater
high-risk sexual behaviours, including sex trading, multiple
sex partners and sex without a condom, than people who
use drugs but do not inject [11–14].
Objective
This systematic review and meta-analysis sought to
examine whether psychosocial interventions could reduce
injecting and sexual risk behaviours compared to usual
care; education or information; HIV testing and coun-
selling; or interventions of lesser time or intensity (with
and without OST).
Methods
A systematic review with meta-analysis was conducted in
accordance with the Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses [15] and registered
with the International Prospective Register of Systematic
Reviews (PROSPERO 014:CRD42014012969).
Search Strategy
The search strategy is described in Table I of the Supple-
mentary Online document. The following databases were
searched for relevant randomised controlled trials (RCTs)
published from 2000 until 26 May 2015: MEDLINE,
PsycINFO, CINAHL and the Cochrane Collaboration, with
an update search in MEDLINE to 9 December 2016.
Additionally, Clinical Trials databases were searched to
identify additional publications. Forward and backward
searching of references was conducted and reference lists
of recent relevant reviews were cross-checked to verify all
relevant RCTs were included in the current systematic
review.
Eligibility
Citations were included if full text was published in Eng-
lish. Studies were eligible if (1) published during
2000–2016; (2) participants were PWID or results pre-
sented for PWID; (3) they were RCTs; (4) outcome/s
included: (i) any injecting risk behaviour including sharing
of needle/syringes or other injecting paraphernalia, and
injecting frequency, reported separately or as an aggregated
outcome, (ii) any sexual risk behaviour including unpro-
tected sex or number of sexual partners, reported separately
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or as an aggregated outcome; and (5) psychosocial inter-
ventions were compared to a control group, who received
usual care, education or information, HIV testing and
counselling, ‘‘an intervention of lesser time or intensity’’
[9] (with and without OST).
GG and NM independently assessed all abstracts and
potentially eligible full-text manuscripts against eligibility
criteria. Where disagreement regarding study inclusion
occurred, decisions were reached through referral to addi-
tional reviewers, EH, DS, KW.
Data Extraction
DS, KW, JM, and GG extracted the following data on each
study using a checklist: authors, publication year, country,
aim of intervention, participants (% PWID, % females, and
mean age), intervention delivery setting/staff, intervention
description, adherence, description of control interventions,
follow-up duration and results (Table 1). These data were
verified by a second reviewer and differences resolved
through discussion.
Methodological Quality
Two authors (from GG, DS, JM, JT) independently
assessed the trial’s methodological quality across six
domains using the Cochrane Risk of Bias tool [16]:
sequence generation; allocation concealment; blinding of
participants, personnel, and outcome assessors; incomplete
outcome data; selective outcome reporting; and other
sources of bias (Fig. 2). Assessments were compared to
quality assessments from published reviews [5–7, 9], and
differences resolved through discussion with a third
assessor, EH.
Intervention Descriptions
Intervention functions were categorised using The Beha-
viour Change Wheel [10], including: education (increasing
knowledge/understanding), e.g. ‘‘The 30 min pre-test
counseling session provided basic information about…how
to reduce the risk of HIV’’ [17], persuasion (using com-
munication to induce positive/negative feelings/stimulate
action) e.g. ‘‘facilitators…praise[d] their effective com-
munication strategies’’ [18] and ‘‘reaffirmed commitment
to change’’ [19], incentivisation (creating expectation of
reward), e.g. ‘‘Contingent vouchers were given when a
participant provided a cocaine-negative urine specimen’’
[20], training (imparting skills), e.g. ‘‘skills building to
teach personal risk reduction and negotiation’’ [21] and
‘‘technical condom use and syringe disinfection skills’’
[22], modelling (providing example/s for people to aspire
to/imitate), e.g. ‘‘model injection and sexual risk reduction
behaviors with their risk network members’’ [23] and
‘‘demonstration and rehearsal of syringe cleaning’’ [19],
and enablement (increasing means/reducing barriers) e.g.
‘‘women created a personalized risk-reduction plan’’ [24],
‘‘goal-setting for HIV risk reduction’’ [25] and role play
‘‘to help identify barriers to safer injection’’ [26] (Table 1).
Functions that related directly to the intervention’s target
behaviour/s were coded. GG and DS independently deter-
mined intervention functions. Disagreements were resolved
through discussion. Intervention functions assigned to five
trials were validated by a behaviour change expert.
Statistical Analysis
The principal summary measure was the standardized
mean difference (SMD). As outcome data were presented
as dichotomous or continuous data across included RCTs,
odds ratios (OR) were recalculated as SMD to allow data
pooling. The standard errors of log OR were converted to
standard errors of a SMD by multiplying by the same
constant (H3/p = 0.5513). This allowed the standard error
for the log OR and hence a confidence interval (CI) to be
calculated. For each RCT, the SMD and corresponding
95% CIs for the assessed outcome were retrieved or cal-
culated [27]. Data entry and statistical analysis were per-
formed using Review Manager Software. Where RCTs
reported data from various follow-up periods, data from the
latest follow-up period were included in the meta-analysis,
combining outcomes assessed at multiple time periods. To
determine whether RCTs included in the meta-analysis
were consistent, the degree of heterogeneity was calcu-
lated. I2 of 25% was considered low, 50% moderate and
75% high heterogeneity [28]. In the inverse variance
method, individual effect sizes were weighted according to
the reciprocal of their variance calculated as the square of
the standard error.
Main and Subgroup Analysis
In line with a recent Cochrane review [7] and in an attempt
to address the complexity of clinical heterogeneity of
interventions, sub-group analyses were conducted to com-
pare psychosocial interventions with (1) treatment as usual;
(2) education or information; (3) HIV testing and coun-
selling; and (4) control interventions of lesser time or
intensity with and (5) without OST. As follow-up duration
may affect intervention effectiveness, further sub-group
analyses were conducted where possible, comparing length
of time in months from the end of the intervention to the
final follow-up of included trials (i.e. B3, 4–6, and
C9 months follow-up).
Where RCTs included in the meta-analyses had more
than one intervention group [17, 20, 29], data from the
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psychosocial intervention most relevant to the aims of this
systematic review were compared to the control interven-
tion. For Booth et al. [17], the most relevant intervention
condition was considered treatment as usual (TAU) ? -
HIV/HCV counselling and education (C&E), rather than
TAU ? a therapeutic alliance to facilitate treatment entry.
For Sterk et al. [29], the enhanced negotiation intervention
(ENI) was considered more relevant than the enhanced
motivation intervention (EMI). For Schroder et al. [20],
TAU? weekly CBT ? contingent vouchers (CM)
(CBT ? CM) was considered superior to both weekly
CBT ? noncontingent vouchers and CM ? weekly group
therapy, and therefore selected as the intervention condi-
tion for the meta-analysis. Go et al. [30] conducted a multi-
level intervention using a 2 9 2 (four-arm) factorial design
consisting of: (1) standard of care (i.e. HIV testing and
counselling); (2) structural-level community stigma
reduction programme; (3) individual-level post-test coun-
selling and skill-building support groups; (4) both indi-
vidual and structural level activities. For the purpose of this
systematic review, the individual-level post-test coun-
selling and skill-building support groups will be compared
to individual standard of care.
Random effect models were applied to compare the fol-
lowing outcomes of interest for meta-analysis by type of control
intervention, and by type of control intervention and length of
follow-up post intervention: any injecting risk behaviour
(Fig. 3a; Table 2) including sharing of needle/syringes
(Fig. 3b; Table 2) or other injecting paraphernalia (Fig. 3c;
Table 2), and frequency of injecting (Fig. 3d; Table 2),
reported separately or as an aggregated outcome; and any
sexual risk behaviour (Fig. 4a; Table 3) including unprotected
sex (Fig. 4b; Table 3) or number of sexual partners (Fig. 4c;
Table 3), reported separately or as an aggregated outcome.
Results
Study Selection
Database searches to 26 May 2015 resulted in 2493 citations;
an additional 77 citations were identified from 1 January
2015 to 9 December 2016 (Fig. 1). One additional manu-
script was identified from hand-searching other reviews’
reference lists. After removal of duplicates, 1903 citations
remained. In total, 1771 abstracts were excluded as they did
not meet eligibility criteria and 132 abstracts were selected
for full-text assessment, including four related manuscripts
referenced in these selected texts. Eighty-nine articles were
excluded as: they were not RCTs (n = 34); outcomes of
interest were not assessed/presented (n = 29); outcomes
were not presented by PWID (n = 6); number of PWID was
not reported (n = 4); or the intervention was not
psychosocial (n = 4). Additionally, ten manuscripts were
excluded as intervention group outcomes were not compared
or did not evaluate the intervention’s effect. One further
manuscript was excluded because both treatment arms
received the same psychosocial intervention; the interven-
tion arm received a 90-day free OST coupon. One manu-
script published in Chinese was excluded [a full list of
excluded references available on request].
Forty-two manuscripts from 32 RCTs were eligible
[17–26, 29–55]. The meta-analyses included 24 trials
[17–22, 24, 25, 29–31, 33, 38, 39, 41, 43, 46–52, 54]. Eight
trials were excluded from the meta-analysis for: not pro-
viding the number of PWID for control and intervention
groups at follow-up [32, 34, 35, 45, 53], only providing risk
ratios [37], outcome combined HIV with sexually trans-
mitted infections [26] and data for ‘unsafe injection prac-
tices’ was only presented at baseline [23].
Quality Assessment
Risk of bias varied across RCTs (Fig. 2). Incomplete outcome
data was the most common risk of bias, but selective outcome
reporting contributed to risk of bias for some trials. Other
potential sources included altering randomisation protocols
depending on number of participants enrolled on a particular
day [41], significant baseline differences between groups in
outcome of interest [31], variation in the TAU group across sites
[17]; possible cross-over contamination between groups
[18, 24, 38, 39, 41, 50], a high proportion of excluded indi-
viduals who differed significantly to those included [20], and
large variations reported in follow-up period [23].
Study Characteristics
Characteristics of included RCTs are described in Table 1
(and more detail is presented in the Online Supplementary
document Table II). In total, 12,840 participants (35%
female; range 0–100%) were enrolled; the majority were
PWID (84.5%) (range 16–100%). Most trials (n = 18)
were conducted in the US [17, 19–21, 25, 29, 32, 34, 35,
38, 41, 43, 45, 47, 49, 51–53]; three in Russia [23, 24, 50];
two in Canada [33, 37]; two in Vietnam [30, 39]; and one
in Kazakhstan [22]; Georgia [46]; Australia [54]; the UK
[31]; Mexico [26]; and Puerto Rico [48]. One trial was
conducted in both the US and Thailand [18].
Trials included in the systematic review compared
psychosocial interventions with usual care (n = 4)
[17, 37, 51, 52], education or information (n = 9)
[19, 25, 26, 33, 34, 39, 46, 53, 54], HIV testing and
counselling (n = 5) [18, 30, 45, 48, 49], interventions of
lesser time or intensity with (n = 12)
[21–23, 29, 31, 32, 35, 38, 41, 47, 50] and without OST
(n = 2) [20, 43].
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Of the 32 interventions delivered in the RCTs, most
(n = 14) were delivered to individual participants
[17, 19, 20, 24, 26, 29, 31, 33, 37, 48, 51–54]; eight were
delivered to groups [18, 23, 32, 34, 38, 39, 41, 49] and two to
couples [35, 45]. The remaining eight trials delivered inter-
ventions in a combination of ways e.g. individual and couples
sessions[46]; individual and group sessions [18, 25, 43, 47, 50];
group and couples sessions [22] and one trial provided both
individual and structural level activities [30]. For interventions
with more than one session, retention or adherence to the
intervention ranged from 50% [17] to 95% [29] (further detail
provided in the Online Supplementary Table II).
Eight interventions incorporated peer mentoring from an
index participant to change the behaviours of other PWID
[18, 21, 23, 25, 38, 39, 41, 47, 49]. The majority of
interventions contained at least three sessions (n = 25) [18,
20–23, 25, 29–32, 34, 35, 37–39, 41, 43, 46–50, 52, 53],
four interventions contained two sessions [17, 24, 44, 51]
and three interventions one session [26, 33, 54].
On the whole, interventions were delivered in drug treatment
settings including outpatient and hospital clinics
[20, 21, 31, 48–50]; methadone maintenance clinics [32, 43];
inpatient or residential detoxification units [17, 24, 54]; needle
and syringe exchanges [22, 37] or outreach [49] (settings not
mutually exclusive). In addition, the vast majority of studies
were delivered by clinic staff in the treatment setting as opposed
to researcher delivered (or not specified) (Table 1).
Outcomes
Various validated and other purposely developed instruments
were used to assess injecting behaviour in 32 trials
[17–26, 29–35, 37–39, 41, 43, 45–52, 54] and sexual behaviour
in 24 trials [17–26, 29–32, 34, 35, 38, 39, 43, 45, 47, 49, 50, 54].
The most common reporting timeframe for outcomes was in the
past 30 days(n = 19) [17, 18, 22–26, 29, 32–34,
43, 46, 48–52, 54], followed by the past 3 months (n = 10)
[23, 30, 32, 35, 38, 39, 41, 45, 47, 50] or 6 months (n = 3)
[21, 25, 53], past week (n = 2) [20, 37] or behaviour at the last
sexual encounter or injecting event (n = 1) [19] (answers not
mutually exclusive as three trials reported different reporting
timeframe for different outcomes) [23, 25, 50].
Results of Individual RCTs Not Included
in the Meta-analyses
Of the eight trials omitted from the meta-analyses, three
reported that psychosocial interventions showed greater
reductions in injecting risk behaviours than education/in-
formation, usual care or HIV testing and counselling
[26, 37, 45] and three reported that psychosocial inter-
ventions showed greater reductions in sexual risk beha-
viours than or HIV testing and counselling [32, 35, 45].T
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Meta-analyses
Any Injecting Risk Behaviour
Twenty-two RCTs assessed any injecting risk behaviour
(Fig. 3a). Psychosocial interventions independently
reduced injecting risk behaviours more than control
interventions in seven trials [21, 22, 25, 38, 41, 46, 48]. A
total of 3096 and 2971 PWID were included in the inter-
vention and control groups respectively. Overall, psy-
chosocial interventions showed a greater reduction in any
injecting risk behaviour (SMD -0.29; 95% CI -0.42 to
-0.15; I2 = 61%; p =\0.01) than control interventions
(Fig. 3a). Psychosocial interventions also demonstrated
Ϯ Includes 6 trials listed in the clinical trials database for which no published papers could be found.
* Includes 4 related manuscripts referenced in potentially eligible manuscripts
Records idenﬁed from electronic 
database searches
(n = 2570)
Sc
re
en
in
g
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cl
ud
ed
El
ig
ib
ili
ty
Id
en
ﬁ
ca
o
n
Records aer duplicates removed 
(n = 1903) 
Abstracts screened
(n = 1903)
Records excluded
(n =  1771)Ϯ
Full-text manuscripts 
assessed for eligibility 
(n = 132)*
Full-text manuscripts excluded
(n = 89)
• 34 not RCT
• 29 outcomes of interest not 
assessed/not presented 
• 10 did not compare intervenon 
condions/did not evaluate eﬀect 
of intervenon
• 6 results not reported by PWID
• 4 not conducted among PWID
• 4 intervenon not psychosocial 
• 1 both treatment groups received 
same psychosocial intervenon
• 1 manuscript published in Chinese
Manuscripts included          
in systemac review
(n = 43) Trials (n = 32)
Trials included                
in meta-analysis
(n = 24)
Records idenﬁed from other 
sources
(n = 1)
Fig. 1 Flowchart.  Includes 6 trials listed in the clinical trials database for which no published papers could be found. *Includes 4 related
manuscripts referenced in potentially eligible manuscripts
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greater reductions in any risk behaviours than education/
information (SMD -0.41; 95% CI -0.79 to -0.04;
I2 = 62%; p = 0.03); HIV testing and counselling (SMD
-0.24; 95% CI -0.44 to -0.03; I2 = 0%; p = 0.02);
interventions of a lesser time or intensity (SMD -0.34;
95% CI -0.56 to -0.12; I2 = 75%; p\ 0.01), but no
difference was found when compared with interventions of
a lesser time or intensity that included OST (SMD 0.23;
95% CI 0.51–0.97; I2 = 0%; p\ 0.01) or treatment as
usual (SMD -0.09; 95% CI -0.32 to 0.15; I2 = 26%;
p = 0.54). Where outcomes were assessed B3 or
4–6 months post-intervention, psychosocial interventions
reduced any injecting risk behaviour when compared with
interventions of lesser time or intensity. Where outcomes
were compared C9 months post-intervention, psychosocial
interventions reduced any injecting risk behaviour more
than interventions that provided education/information
alone (Table 2). Heterogeneity was moderate in psy-
chosocial interventions compared to education/information
(I2 = 62%), possibly due to the variations in the mode of
delivery and intervention components (Table 1). The edu-
cation/information interventions in the control conditions
included a pamphlet compared to a 6 session education/
enablement intervention [39] and ranged from comparing a
one-session education intervention with a one-session
motivational intervention [33], to comparing 22 education
sessions with referrals to drug treatment with a 22-week
intervention including motivational interviewing counsel-
ing sessions for both the male participant and the couple,
monetary incentives for drug abstinence, and research-
supported detoxification followed by naltrexone treatment
[46]. There was high heterogeneity in the analysis of psy-
chosocial interventions compared to interventions of a
lesser time or intensity (without OST) (I2 = 75%) for
similar reasons to those mentioned above. Six trials
included equal-attention control conditions ranging from 2
[24] to 10 [41] sessions, and three included control inter-
ventions with fewer sessions, ranging from four versus one
session [31] to ten versus eight sessions [47] (Table 1). All
but one trial [31] had at least two sessions in the control
and/or intervention conditions. One trial compared a two-
session woman focused intervention with a two-session
nutritional intervention [24]. The variation in intervention
duration and content across conditions contributes to the
high heterogeneity.
Sharing Needles and Syringes
Thirteen RCTs assessed sharing of needles/syringes
(Fig. 3b). Psychosocial interventions reduced this beha-
viour more than the control interventions in five of those
trials [21, 22, 43, 46, 48]. A total of 1411 and 1315 PWID
were included in the intervention and control groupsFig. 2 Risk of bias for included trials
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respectively. Overall, psychosocial interventions reduced
the sharing of needle/syringes (SMD -0.43; 95% CI -0.69
to -0.18; I2 = 68%; p\ 0.01) compared with control
interventions. Psychosocial interventions reduced needle
and syringe sharing compared with education/information
(SMD -0.52; 95% CI -1.02 to -0.03; I2 = 10%;
p = 0.04); or HIV testing and counselling (SMD -0.24;
95% CI -0.44 to -0.03; I2 = 0%; p = 0.02); but no dif-
ference was found when compared with interventions of a
lesser time or intensity (SMD -0.56; 95% CI -0.12 to
0.09; I2 = 90%; p = 0.09), interventions of a lesser time
or intensity that included OST (SMD -0.13; 95% CI
-1.32,1.05; I2 = 63%; p = 0.83) or treatment as usual
(SMD -0.53; 95% CI -1.12 to 0.07; p = 0.08; one trial).
Where outcomes were assessed B3 or 4–6 months post-
intervention, psychosocial interventions reduced needle
and syringe sharing more than interventions of lesser time
or intensity. Where outcomes were assessed 4–6 months
post-intervention, a greater reduction in any injecting risk
behaviour was found for psychosocial interventions com-
pared with HIV testing and counselling (Table 2). There
was moderate and high heterogeneity in the analysis of
psychosocial interventions compared to interventions of a
lesser time or intensity with (I2 = 63%) and without OST
(I2 = 90%), again potentially explained by the differences
in intervention content and delivery. The two trials that
compared psychosocial interventions with OST to inter-
ventions of a lesser time/intensity with OST varied in
length of OST treatment. Both included a 12-week psy-
chosocial intervention, however, the trial where methadone
was prescribed for six months independently reduced
needle and syringe sharing [43] and the trial that prescribed
methadone for three months did not [20]. Four trials
compared psychosocial interventions with interventions of
a lesser time or intensity without OST, two delivered to
couples [22] or encouraged peer outreach [21] indepen-
dently reduced needle and syringe sharing, whereas those
delivered to individuals on their own or in groups did not
[29, 50].
Sharing Other Injecting Paraphernalia
Seven RCTs assessed sharing of injecting paraphernalia (other
than needles/syringes) (Fig. 3c). None independently found
the psychosocial intervention to be more efficacious than the
control interventions. A total of 1209 and 1157 PWID were
included in the intervention and control groups respectively.
Overall, psychosocial interventions showed greater reduc-
tions in the sharing of other injecting paraphernalia (SMD
-0.21; 95% CI -0.34 to -0.09; I2 = 0%; p\ 0.01) com-
pared with control interventions. Psychosocial interventions
reduced the sharing of other injecting paraphernalia more than
interventions of a lesser time or intensity without OST (SMD
-0.24; 95% CI -0.42 to -0.06; I2 = 0%; p\ 0.01); but no
differences were found when compared with education/in-
formation (SMD-0.42; 95% CI-0.98 to 0.14; p = 0.15; one
trial); and HIV testing and counselling (SMD -0.17; 95% CI
-0.34 to 0.00; I2 = 0%; p = 0.05). Where outcomes were
compared 4–6 months post-intervention, psychosocial inter-
ventions significantly reduced sharing of other injecting
paraphernalia compared with interventions of lesser time or
intensity (Table 2).
Injecting Frequency
Eight RCTs assessed frequency of injecting (Fig. 3d).
Psychosocial interventions independently reduced fre-
quency of injecting compared with the control interven-
tions in four trials [29, 46, 48, 49]. A total of 1168 and
1177 PWID were included in the intervention and control
groups respectively. Overall, psychosocial interventions
showed no difference in reducing frequency of injecting
(SMD -0.17; 95% CI -0.35 to 0.00; I2 = 61%;
p = 0.05). Psychosocial interventions significantly reduced
the frequency of injecting compared with education/infor-
mation (SMD -1.05; 95% CI -2.07 to -0.03; p = 0.04;
one trial); but no difference was found when compared
with interventions of a lesser time or intensity with (SMD
0.09; 95% CI -0.61 to 0.79; I2 = 76%; p = 0.20; one
trial) and without OST (SMD -0.46; 95% CI -1.02 to
0.21; I2 = 66%; p = 0.80); HIV testing and counselling
(SMD -0.16; 95% CI -0.40 to 0.08; I2 = 76%; p = 0.20)
and treatment as usual (SMD -0.00; 95% CI -0.20 to
0.21; p = 0.96; one trial). Where outcomes were compared
4–6 months post-intervention, the frequency of injecting
significantly reduced for participants receiving psychoso-
cial interventions compared with participants receiving
education/information (Table 2). There was moderate to
high heterogeneity in the analysis comparing psychosocial
interventions to HIV testing and counselling (I2 = 76%)
and to interventions of a lesser time/intensity with
(I2 = 66%) and without OST (I2 = 66%), again potentially
explained by the differences in intervention content and
delivery described above. All HIV testing and counselling
intervention control groups received two sessions com-
pared to the intervention conditions that ranged from seven
[49] to ten sessions [18] in comparison.
bFig. 3 Efficacy of psychosocial interventions versus control inter-
ventions in reducing a ANY injecting risk behaviours among people
who inject drugs, b sharing of needles or syringes among people who
inject drugs, c sharing of other injecting equipment (not needle/
syringes) among people who inject drugs, d frequency of injecting
among people who inject drugs
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Any Sexual Risk Behaviour
Ten RCTs assessed any sexual risk behaviour (Fig. 4a).
Psychosocial interventions were independently more likely
to reduce any sexual risk behaviour than the control
interventions in two trials [22, 24]. A total of 1359 and
1409 PWID were included in the intervention and control
groups respectively. Overall, psychosocial interventions
reduced any sexual risk behaviour compared with control
interventions (SMD -0.19; 95% CI -0.39, 0.01;
I2 = 58%; p = 0.07). Psychosocial interventions showed
no difference in reducing any sexual risk behaviours
compared with education/information (SMD -0.12; 95%
CI -0.32 to 0.09; I2 = 34%; p = 0.27), interventions of a
lesser time or intensity with (SMD -0.26; 95% CI -0.67
to 0.15; I2 = 78%; p = 0.21); and without OST (SMD
-0.17; 95% CI -1.41,1.07; I2 = 72%; p = 0.79); and
HIV testing and counselling (SMD 0.14; 95% CI
-0.81,1.09; p = 0.77; one trial). Where outcomes were
compared B3 months post-intervention, psychosocial
interventions reduced any sexual risk behaviour compared
with interventions of a lesser time or intensity (without
OST) (Table 3). The high heterogeneity in the analysis
comparing psychosocial interventions to interventions of a
lesser time or intensity with (I2 = 78%) and without OST
(I2 = 72%) has already been discussed.
Fig. 3 continued
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Unprotected Sex
Eight RCTs assessed unprotected sex (Fig. 4b). Psy-
chosocial interventions were independently more effective
than the control interventions in four trials [22, 24, 29, 43].
A total of 876 and 930 PWID were included in the inter-
vention and control groups respectively. Overall, psy-
chosocial interventions reduced unprotected sex more than
control interventions (SMD -0.27; 95% CI -0.54 to
-0.01; I2 = 68%; p = 0.04). Psychosocial interventions
reduced unprotected sex compared with interventions of a
lesser time or intensity (without OST) (SMD -0.44; 95%
CI -0.86 to -0.01; I2 = 79%; p = 0.04); but no differ-
ence was reported when compared with education/infor-
mation (SMD 0.03; 95% CI -0.18 to 0.24; p = 0.79; one
trial), interventions of a lesser time or intensity with OST
(SMD -0.13; 95% CI -1.21 to 0.94; I2 = 70%;
p = 0.81); and HIV testing and counselling (SMD 0.14;
95% CI -0.81,1.09; p = 0.77; one trial). Where outcomes
were compared B3 and 4–6 months post-intervention,
psychosocial interventions reduced unprotected sex com-
pared to interventions of a lesser time or intensity (without
OST). Where outcomes were assessed C9 months post-
intervention, psychosocial interventions reduced unpro-
tected sex compared with interventions of a lesser time or
intensity (with OST) (Table 3).
Number of Sexual Partners
Two RCTs assessed number of sexual partners (Fig. 4c). A
total of 135 and 140 PWID were included in the inter-
vention and control groups respectively. There was no
difference between psychosocial interventions and educa-
tion/information in reducing the number of sexual partners
(SMD 0.01; 95% CI -0.14 to 0.17; one trial). Interventions
of a lesser time or intensity (without OST) reduced the
number of sexual partners compared with psychosocial
interventions (SMD 3.24; 95% CI 2.36,4.12; one trial).
Discussion
The aim of the review and meta-analysis was to identify
and evaluate the impact of psychosocial interventions
designed to reduce injecting risk and sexual risk behaviours
among PWID. A total of 24 trials were included in the
meta-analysis. Overall, psychosocial interventions reduced
some of the target injecting (sharing of needle and syringes
and other injecting paraphernalia) and sexual risk beha-
viour (unprotected sex) outcomes among PWID when
compared with control conditions. More specifically, the
meta-analysis found that psychosocial interventions
reduced the sharing of needles and syringes compared to
education/information or HIV testing and counselling,
reduced the sharing of other injecting paraphernalia com-
pared to interventions of a lesser time or intensity, reduced
the frequency of injecting compared to one trial of edu-
cation/information, and reduced unprotected sex compared
to interventions of a lesser time or intensity. Although
psychosocial interventions targeted injecting risk beha-
viours rather than a reduction in injecting behaviour per se,
one trial reported a significant effect (p = 0.05) with
regards to reduced frequency of injecting. Psychosocial
interventions were no more likely than control interven-
tions to reduce the number of sexual partners. However,
only two trials were pooled in this specific meta-analysis,
and many participants reported being in a steady relation-
ship. Interestingly, they also reported a reduction in
unprotected sex, a factor which may be more important in
reducing BBV transmission than the number of sex part-
ners [25, 29].
Using data on outcomes collected at nine-months or
more post-intervention, the meta-analyses found psy-
chosocial interventions produced more reported behaviour
change than control interventions, suggesting that mainte-
nance or booster sessions may be required to sustain pos-
itive behaviour change.
One study found stronger intervention effects for those
who had known their HCV-positive status for at least six
months, but not for those who had known their HCV-
positive status for more than 12 months [41], suggesting a
window of opportunity may exist following HCV diagnosis
to address transmission risks.
Overall and regardless of intervention or control con-
tent, 16 of the 32 trials included in the systematic review
reported greater reductions in injecting or sexual risk
behaviours in participants in the intervention group com-
pared to the control group
[21, 22, 24–26, 29, 32, 35, 37, 38, 41, 43, 45, 46, 48, 49].
Only two trials in the review (with small sample sizes)
included contingency management (incentivisation). One
of these trials reported greater reductions in injecting risk
behaviours in the intervention group (22 sessions of
motivational interviewing for the male participant and
couple (female partner drug-free) plus contingency man-
agement and naltrexone) compared to the control group (22
sessions of education, including referrals to a detoxification
programme and aftercare that may or may not have
included naltrexone) [46]. The other reported no significant
difference in injecting or sexual risk behaviours between
the intervention (29 week intervention including 12 weeks
bFig. 4 Efficacy of psychosocial interventions versus control inter-
ventions in reducing a ANY sexual risk behaviours among people
who inject drugs, b unprotected sex among people who inject drugs,
c number of sexual partners among people who inject drugs
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of CBT and contingent vouchers (as well as standard care:
methadone ? 5 weekly individual counselling, followed
by 12 weeks standard treatment) and control groups
(29 week standard care intervention (same as intervention
group) including 12 weeks of group therapy and non-
contingent vouchers) [20] (Table 1). Only three of the
seven trials [18, 19, 26, 33, 37, 43, 53] of psychosocial
interventions including motivational interviewing found
greater reductions in some injecting and sexual risk beha-
viours [26, 37, 43]. As these three interventions varied in
content and participant group (e.g. one session interactive
session for female sex workers [26]; computerised inter-
vention (69% male) [37]; and PWID entering OST (70%
male) [43]; results about the effectiveness of specific
intervention functions (e.g. incentivisation or persuasion)
in reducing BBV risk behaviours among PWID are
inconclusive.
Limitations
Limitations include the low number of studies for inclusion
in some of the sub-group analyses of behavioural outcomes
and intervention delivery modes. In addition, there was
heterogeneity in terms of the interventions studied and their
duration, as well as differences in sample sizes and char-
acteristics, length of follow-up, and assessment methods
used to determine risk behaviours. This lack of consistency
across studies may have contributed to the moderate levels
of heterogeneity noted in the meta-analyses. The most
common risk of bias in included RCTs was selective out-
come reporting and possible cross-over contamination
between groups. A further limitation is that authors of the
eight trials not included in the meta-analysis were not
contacted to determine whether they could supply the
additional data required to include the trial in the meta-
analysis. It is acknowledged that this could have resulted in
a potential source of bias in the findings. These limitations
need to be considered when interpreting the results.
Conclusions
Whilst indications from the meta-analysis suggest that
psychosocial interventions (when compared to control)
reduce risk taking behaviour outcomes, more research is
needed. The findings highlight the difficulty and com-
plexity involved in attempting to examine the effectiveness
of interventions that include different content and func-
tions, modes of delivery, dosage and number of sessions.
This heterogeneity in both the control and intervention
conditions resulted in challenges to fully interpret the
findings. It will be important to determine what types of
psychosocial interventions work for whom and in what
settings [8]. Our findings suggest that psychosocial inter-
ventions could boost the impact of current harm reduction
interventions delivered as routine care and could be
included with other harm reduction approaches, including
OST and needle and syringe exchange, to reduce BBV
transmission risks among PWID. Further trials should
address some of the limitations in terms of target popula-
tions, dose and frequency and timing of outcome measures.
Acknowledgements This manuscript presents independent research
funded by the National Institute for Health Research (NIHR) under
the Health Technology Assessment programme [project number
13/17/04]. The findings from this review will also be published as part
of the full project report ‘‘Preventing blood borne virus infection in
people who inject drugs in the UK: the development and feasibility of
psychosocial interventions’’ in Health Technology Assessment. The
views expressed in this publication are those of the authors and not
necessarily those of the NHS, the NIHR or the Department of Health.
We are grateful to Dr Benjamin Gardner from King’s College London
for his assistance with determining intervention functions on a sub
sample of trials included in this review.
Compliance with Ethical Standards
Conflict of interest The authors declare that they have no conflict of
interest.
Ethical Approval For this type of study formal consent is not
required.
Informed Consent For this type of study informed consent is not
required.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://crea
tivecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
References
1. Hahne´ SJ, Veldhuijzen IK, Wiessing L, Lim TA, Salminem M,
Laar MV. Infection with hepatitis B and C virus in Europe: a
systematic review of prevalence and cost-effectiveness of
screening. BMC Infect Dis. 2013;13:181.
2. Mathers BM, Degenhardt L, Phillips B, et al. Global epidemi-
ology of injecting drug use and HIV among people who inject
drugs: a systematic review. Lancet. 2008;372(9651):1733–45.
3. Baeten J, Celum C. Systemic and topical drugs for the prevention
of HIV infection: antiretroviral pre-exposure prophylaxis. Annu
Rev Med. 2013;64:219–32.
4. Aspinall EJ, Corson S, Doyle JS, et al. Treatment of hepatitis C
virus infection among people who are actively injecting drugs: a
systematic review and meta-analysis. Clin Infect Dis.
2013;57(Suppl 2):S80–9.
5. MacArthur GJ, van Velez E, Palmateer N, et al. Interventions to
prevent HIV and Hepatitis C in people who inject drugs: a review
of reviews to assess evidence of effectiveness. Int J Drug Policy.
2014;25(1):34–52.
AIDS Behav
123
6. Hagan H, Pouget ER, Des Jarlais DC. A systematic review and meta-
analysis of interventions to prevent hepatitis C virus infection in people
who inject drugs. J Infect Dis. 2011;204(1):74–83.
7. Meader N, Li R, Des Jarlais DC, Pilling S. Psychosocial inter-
ventions for reducing injection and sexual risk behaviour for
preventing HIV in drug users. Cochrane Database Syst Rev.
2010;1:CD007192.
8. Meader N, Semaan S, Halton M, et al. An international system-
atic review and meta-analysis of multisession psychosocial
interventions compared with educational or minimal interven-
tions on the HIV sex risk behaviors of people who use drugs.
AIDS Behav. 2013;17(6):1963–78.
9. Sacks-Davis R, Horyniak D, Grebely J, Hellard M. Behavioural
interventions for preventing hepatitis C infection in people who
inject drugs: a global systematic review. Int J Drug Policy.
2012;23(3):176–84.
10. Michie S, van Stralen MM, West R. The behaviour change wheel:
a new method for characterising and designing behaviour change
interventions. Implement Sci. 2011;6:42.
11. Harrell PT, Mancha BE, Petras H, Trenz RC, Latimer WW.
Latent classes of heroin and cocaine users predict unique HIV/
HCV risk factors. Drug Alcohol Depend. 2012;122(3):220–7.
12. Booth RE, Strathdee SA. Baseline findings from the third col-
laborative injection drug users study/drug users intervention trial
(CIDUS III/DUIT). Drug Alcohol Depend. 2007;91(Suppl
1):S1–3.
13. Gilchrist G, Singleton N, Donmall M, Jones A. Prevalence and
factors associated with sex trading in the year prior to entering
treatment for drug misuse in England. Drug Alcohol Depend.
2015;152:116–22.
14. Jin H, Huriaux E, Loughran E, Packer T, Raymond HF. Differ-
ences in HIV risk behaviors among people who inject drugs by
gender and sexual orientation, San Francisco, 2012. Drug Alcohol
Depend. 2014;145:180–4.
15. Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group.
Preferred reporting items for systematic reviews and meta-anal-
yses: the PRISMA statement. J Clin Epidemiol.
2009;62(10):1006–12.
16. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane
Collaboration’s tool for assessing risk of bias in randomised tri-
als. BMJ. 2011;343:d5928.
17. Booth RE, Campbell BK, Mikulich-Gibertson SK, et al. Reduc-
ing HIV-related risk behaviors among injection drug users in
residential detoxification. AIDS Behav. 2011;15(1):30–44.
18. Latkin CA, Donell D, Metzger D, et al. The efficacy of a network
intervention to reduce HIV risk behaviors among drug users and
risk partners in Chiang Mai, Thailand and Philadelphia, USA.
Soc Sci Med. 2009;68(4):740–8.
19. Zule WA, Costenbader EC, Curtis CM, Wechsberg WM. Effects
of a hepatitis C virus educational intervention or a motivational
intervention on alcohol use, injection drug dse, and sexual risk
behaviours among injection drug users. Am J Public Health.
2009;99(Suppl 1):S180–6.
20. Schroeder JR, Epstein DH, Umbricht A, Preston KL. Changes in
HIV risk behaviors among patients receiving combined phar-
macological and behavioral interventions for heroin and cocaine
dependence. Addict Behav. 2006;31(5):868–79.
21. Latkin CA, Sherman S, Knowlton A. HIV prevention among drug
users: outcome of a network-oriented peer outreach intervention.
Health Psychol. 2003;22(4):332–9.
22. Gilbert L, El-Bassel N, Terlikbayeva A, et al. Couple-based HIV
prevention for injecting drug users in Kazakhstan: a pilot inter-
vention study. J Prev Interv Community. 2010;38(2):162–76.
23. Hoffman IF, Latkin CA, Kukhareva PV, et al. A peer-educator
network HIV prevention intervention among injection drug users:
results of a randomized controlled trial in St. Petersburg, Russia.
AIDS Behav. 2013;17(7):2510–20.
24. Wechsberg WM, Krupitsky E, Romanova T, et al. Double jeop-
ardy-drug and sex risks among Russian women who inject drugs:
initial feasibility and efficacy results of a small randomized
controlled trial. Subst Abuse Treat Prev Policy. 2012;7:1.
25. Tobin KE, Kuramoto SJ, Davey-Rothwell MA, Latkin CA. The
STEP into Action study: a peer-based, personal risk network-
focused HIV prevention intervention with injection drug users in
Baltimore, Maryland. Addiction. 2011;106(2):366–75.
26. Strathdee SA, Abramovitz D, Lozada R, et al. Reductions in HIV/
STI incidence and sharing of injection equipment among female
sex workers who inject drugs: results from a randomized con-
trolled trial. PLoS ONE. 2013;8(6):e65812.
27. Bland JM, Altman DG. Statistics notes. The odds ratio.
BMJ.2000;320:1468.
28. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring
inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.
29. Sterk CE, Theall KP, Elifson KW, Kidder D. HIV risk reduction
among African-American women who inject drugs: a randomized
controlled trial. AIDS Behav. 2003;7(1):73–86.
30. Go VF, Frangakis C, Minh NL, et al. Efficacy of a multi-level
intervention to reduce injecting and sexual risk behaviors among
HIV-infected people who inject drugs in Vietnam: a four-arm
randomized controlled trial. PLoS ONE. 2015;10(5):e0125909.
31. Abou-Saleh M, Davis P, Rice P, et al. The effectiveness of
behavioural interventions in the primary prevention of hepatitis C
amongst injecting drug users: a randomised controlled trial and
lessons learned. Harm Reduct J. 2008;5:25.
32. Avants SK, Margolin A, Usubiaga MH, Doebrick C. Targeting
HIV-related outcomes with intravenous drug users maintained on
methadone: a randomized clinical trial of a harm reduction group
therapy. J Subst Abuse Treat. 2004;26(2):67–78.
33. Bertrand K, Roy E´, Vaillancourt E´, Vandermeerschen J, Berbiche
D, Boivin JF. Randomized controlled trial of motivational
interviewing for reducing injection risk behaviours among people
who inject drugs. Addiction. 2015;110(5):832–41.
34. Dushay RA, Singer M, Weeks MR, Rohena L, Gruber R. Low-
ering HIV risk among ethnic minority drug users: comparing
culturally targeted intervention to a standard intervention. Am J
Drug Alcohol Abuse. 2001;27(3):501–24.
35. El-Bassel N, Gilber L, Wu E, et al. Couple-based HIV Prevention
for low-income drug users from New York City: a randomized
controlled trial to reduce dual risks. J Acquir Immune Defic
Syndr. 2011;58(2):198–206.
36. Epstein DH, Hawkins WE, Covi L, Umbricht A, Preston KL.
Cognitive-behavioral therapy plus contingency management for
cocaine use: findings during treatment and across 12-month fol-
low-up. Psychol Addict Behav. 2003;17(1):73–82.
37. Gagnon H, Godin G, Alary M, Bruneau J, Otis J. A randomized
trial to evaluate the efficacy of a computer-tailored intervention to
promote safer injection practices among drug users. AIDS Behav.
2010;14(3):538–48.
38. Garfein RS, Golub ET, Greenberg AE, et al. A peer-education
intervention to reduce injection risk behaviors for HIV and
hepatitis C virus infection in young injection drug users. AIDS.
2007;21(14):1923–32.
39. Go VF, Frangakis C, Le Minh N, et al. Effects of an HIV peer
prevention intervention on sexual and injecting risk behaviors
among injecting drug users and their risk partners in Thai
Nguyen, Vietnam: a randomized controlled trial. Soc Sci Med.
2013;96:154–64.
40. Hershberger SL, Wood MM, Fisher DG. A cognitive-behavioral
intervention to reduce HIV risk behaviors in crack and injection
drug users. AIDS Behav. 2003;7(3):229–43.
AIDS Behav
123
41. Latka MH, Hagan H, Kapadia F, et al. A randomized intervention
trial to reduce the lending of used injection equipment among
injection drug users infected with hepatitis C. Am J Public
Health. 2008;98(5):853–61.
42. Mackesy-Amiti ME, Oullet LJ, Golub ET, Hudson S, Hagan H,
Garfein RS. Predictors and correlates of reduced frequency or
cessation of injection drug use during a randomized HIV pre-
vention intervention trial. Addiction. 2011;106(3):601–8.
43. Margolin A, Avants SK, Warburton LA, Hawkins KA, Shi J. A
randomized clinical trial of a manual-guided risk reduction
intervention for HIV-positive injection drug users. Health Psy-
chol. 2003;22(2):223–8.
44. McMahon JM, Pouget ER, Tortu S, Volpe EM, Torres L,
Rodriguez W. Couple-based HIV counseling and testing: a risk
reduction intervention for US drug-involved women and their
primary male partners. Prev Sci. 2015;16(2):341–51.
45. McMahon JM, Tortu S, Pouget ER, Torres L, Rodriguz W,
Hamid R. Effectiveness of couple-based HIV counseling and
testing for women substance users and their primary male part-
ners: a randomized trial. Adv Prev Med. 2013;2013:286207.
46. Otiashvili D, Kirtadze I. O´Grady KE, Jones HE. Drug use and
HIV risk outcomes in opioid-injecting men in the Republic of
Georgia: behavioral treatment ? naltrexone compared to usual
care. Drug Alcohol Depend. 2012;120(1–3):14–21.
47. Purcell DW, Latka MH, Metsch LR, et al. Results from a ran-
domized controlled trial of a peer-mentoring intervention to
reduce HIV transmission and increase access to care and adher-
ence to HIV medications among HIV-seropositive injection drug
users. J Acquir Immune Defic Syndr. 2007;46(Suppl 2):S35–47.
48. Robles RR, Reyes JC, Colo´n HM, et al. Effects of combined
counseling and case management to reduce HIV risk behaviors
among Hispanic drug injectors in Puerto Rico: a randomized
controlled study. J Subst Abuse Treat. 2004;27(2):145–52.
49. Rotheram-Borus MJ, Rhodes F, Desmond K, Weiss RE. Reduc-
ing HIV risks among active injection drug and crack users: the
safety counts program. AIDS Behav. 2010;14(3):658–68.
50. Samet JH, Raj A, Cheng DM, et al. HERMITAGE—a random-
ized controlled trial to reduce sexually transmitted infections and
HIV risk behaviors among HIV-infected Russian drinkers.
Addiction. 2015;110(1):80–90.
51. Stein MD, Anderson B, Charuvastra A, Maksad J, Friedmann PD.
A brief intervention for hazardous drinkers in a needle exchange
program. J Subst Abuse Treat. 2002;22(1):23–31.
52. Stein MD, Anderson BJ, Solomon DA, et al. Reductions in HIV
risk behaviors among depressed drug injectors. Am J Drug
Alcohol Abuse. 2005;31(3):417–32.
53. Stein MD, Herman DS, Anderson BJ. A trial to reduce hepatitis C
seroincidence in drug users. J Addict Dis. 2009;28(4):389–98.
54. Tucker T, Fry CL, Lintzeris N, et al. Randomized controlled trial
of a brief behavioural intervention for reducing hepatitis C virus
risk practices among injecting drug users. Addiction.
2004;99(9):1157–66.
55. Vera A, Abramovitz D, Lozada R, et al. Mujer Mas Segura (Safer
Women): a combination prevention intervention to reduce sexual
and injection risks among female sex workers who inject drugs.
BMC Public Health. 2012;12:653.
56. Purcell DW, Metsch LR, Latka M, et al. Interventions for
seropositive injectors—research and evaluation: an integrated
behavioral intervention with HIV-positive injection drug users to
address medical care, adherence, and risk reduction. J Acquir
Immune Defic Syndr. 2004;37(Suppl 2):S110–8.
57. Latkin C, Donnell D, Liu T-Y, Davey-Rothwell M, Celentano D,
Metzger D. The dynamic relationship between social norms and
behaviors: the results of an HIV prevention network intervention
for injection drug users. Addiction. 2013;108(5):934–43.
58. Kapadia F, Latka MH, Hagan H, et al. Design and feasibility of a
randomized behavioral intervention to reduce distributive injec-
tion risk and improve health-care access among hepatitis C virus
positive injection drug users: the Study to Reduce Intravenous
Exposures (STRIVE). J Urban Health. 2007;81:99–115.
59. Go VF, Frangakis C, Le Minh N, et al. Effects of an HIV peer
prevention intervention on sexual and injecting risk behaviors
among injecting drug users and their risk partners in Thai
Nguyen, Vietnam: a randomized controlled trial. Soc Sci Med.
2013;96:154–64.
60. Mackesy-Amiti ME, Finnegan L, Ouellet LJ, et al. Peer-educa-
tion intervention to reduce injection risk behaviors benefits high-
risk young injection drug users: a latent transition analysis of the
CIDUS 3/DUIT study. AIDS Behav. 2013;17:2075–83.
61. Mackesy-Amiti ME, Ouellet LJ, Finnegan L, et al. Transitions in
latent classes of sexual risk behavior among young injection drug
users following HIV prevention intervention. AIDS Behav.
2014;18:464–72.
AIDS Behav
123
